Nivolumab: all 1,113 studies that test it

Page 10 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.

• Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)Active, not recruitingNCT03703050Phase 2
• VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerActive, not recruitingNCT03690986Phase 1
• COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.CompletedNCT03667716Phase 1
• An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03661632Phase 1
• A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerCompletedNCT03661320Phase 3
• Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseTerminatedNCT03656627Phase 1
• APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCCTerminatedNCT03655613Phase 1/2
• IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerActive, not recruitingNCT03655002Phase 1
• Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03652233Phase 1
• Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsActive, not recruitingNCT03650894Phase 2
• Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerCompletedNCT03647969Phase 2
• A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT03635892Phase 2
• Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by ElectroporationTerminatedNCT03630640Phase 2
• Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable OsteosarcomaActive, not recruitingNCT03628209Phase 1
• Nivolumab and Relatlimab in Treating Participants With Advanced ChordomaCompletedNCT03623854Phase 2
• DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLActive, not recruitingNCT03620578Phase 2
• A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and NeckCompletedNCT03620123Phase 2
• Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 2
• Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgerySuspendedNCT03604991Phase 2/3
• Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03600155Phase 1
• Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue SarcomasCompletedNCT03590210Phase 2
• Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic TransplantTerminatedNCT03588936Phase 1
• Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid TumorsTerminatedNCT03585465Phase 1/2
• Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin LymphomaCompletedNCT03580408Phase 2
• Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerWithdrawnNCT03576963Phase 1/2
• GMCI, Nivolumab, and Radiation Therapy in Treating Patients with Newly Diagnosed High-Grade GliomasCompletedNCT03576612Phase 1
• A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and NeckActive, not recruitingNCT03576417Phase 3
• Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity StudyCompletedNCT03575598Early Phase 1
• Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal CancerWithdrawnNCT03575234Phase 1
• Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular CarcinomaCompletedNCT03572582Phase 2
• Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance TherapyStatus unknownNCT03569696Phase 2
• A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid TumorsCompletedNCT03565445Phase 1
• Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic CancerActive, not recruitingNCT03563248Phase 2
• Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1
• Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerActive, not recruitingNCT03546686Phase 2
• Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation TherapyCompletedNCT03543189Phase 1/2
• Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedNCT03532217Phase 1
• Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the BladderStatus unknownNCT03529890Phase 2
• Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaActive, not recruitingNCT03528408Phase 2
• Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLCActive, not recruitingNCT03527108Phase 2
• A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesTerminatedNCT03526185Early Phase 1
• Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid TumorsCompletedNCT03525925Phase 1
• Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3
• Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminatedNCT03518320Phase 1
• Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)CompletedNCT03510871Phase 2
• TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)CompletedNCT03475134Phase 1
• Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancErCompletedNCT03469960Phase 3
• Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell CarcinomaCompletedNCT03469713Phase 2
• Immunotherapy + Radiation in Resectable Soft Tissue SarcomaCompletedNCT03463408Early Phase 1
• An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedTerminatedNCT03444753Phase 1
• Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for RecurrenceActive, not recruitingNCT03443856Phase 2
• Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTerminatedNCT03425461Phase 1
• A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerCompletedNCT03425292Phase 1
• An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerWithdrawnNCT03417037Phase 3
• Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast CancerCompletedNCT03409198Phase 2
• A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic CancerCompletedNCT03396211Phase 1
• Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous ChemotherapyWithdrawnNCT03390738Phase 2
• Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyCompletedNCT03387761Phase 1
• An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and NeckWithdrawnNCT03386838Phase 3
• A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationActive, not recruitingNCT03383458Phase 3
• Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular CarcinomaTerminatedNCT03382886Phase 1
• A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCCCompletedNCT03380130Phase 2
• VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerCompletedNCT03373188Phase 1
• Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLCStatus unknownNCT03371992Early Phase 1
• Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma PatientsCompletedNCT03366272Phase 2/3
• Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC PatientsCompletedNCT03351361Phase 3
• iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabActive, not recruitingNCT03350126Phase 2
• Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins LymphomaCompletedNCT03343665Phase 1/2
• A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's LymphomaCompletedNCT03343652Phase 1/2
• Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsTerminatedNCT03342417Phase 2
• Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)WithdrawnNCT03342352Phase 3
• ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT03337919Phase 2
• Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsActive, not recruitingNCT03333616Phase 2
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck TumorsCompletedNCT03317327Phase 1/2
• Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi SarcomaCompletedNCT03316274Early Phase 1
• Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1Status unknownNCT03313544Phase 4
• Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLCompletedNCT03305445Phase 1
• Immunotherapy by Nivolumab for HIV+ PatientsCompletedNCT03304093Phase 2
• Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)CompletedNCT03299946Phase 1
• Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)CompletedNCT03298893Phase 1/2
• Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03297593Phase 2
• ASCT With Nivolumab in Patients With Multiple MyelomaActive, not recruitingNCT03292263Phase 1/2
• Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
• A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03282344Phase 2
• Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasCompletedNCT03277924Phase 1/2
• Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3AActive, not recruitingNCT03245021Phase 1
• Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaStatus unknownNCT03241186Phase 2
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal CancerActive, not recruitingNCT03233711Phase 3
• A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.Active, not recruitingNCT03233152Phase 1/2
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
• Nivolumab in Recurrent and/or Metastatic SCCHNCompletedNCT03226756Phase 2
• Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerActive, not recruitingNCT03223155Phase 1
• Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)Status unknownNCT03219671Phase 2
• A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsCompletedNCT03203876Phase 1
• A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced TumorsCompletedNCT03192943Phase 1
• Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)Status unknownNCT03177239Phase 2
• Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell CarcinomaActive, not recruitingNCT03172754Phase 1/2
• Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder CancerActive, not recruitingNCT03171025Phase 2
• QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2

← Nivolumab overview